Drug Safety Alerts

 

Withdrawn: Zinbryta for Multiple Sclerosis

 

FDA Issues Warning on Risk of Anaphylaxis with Varubi® (Rolapitant)

 

FDA Approves Hydroxyurea for Treatment of Sickle Cell Disease in Children

 

FDA Approves Soliris® (eculizumab) for Myasthenia Gravis

 

FDA Approves Gocovri™ for Treatment of Dyskinesia in Parkinson’s Disease

 

FDA Approves First Generic Three-Times Weekly Formulation of Copaxone

 

FDA Approves New Uses for Two Antiseizure Drugs

 

Recall Notice: Mislabeled Amantadine HCl for Parkinson’s Disease

 

FDA Approves Subcutaneous Belimumab (Benlysta)

 

FDA Approves Endari for Sickle Cell Disease

 

GlaxoSmithKline Recalls Inhalers for Possible Package Leakage

 

FDA Approves Once-Daily Raltegravir

 

FDA: New Warnings for Diabetes Drug Canagliflozin

 

KOĀTE Factor Supply for Hemophilia A is Now Ready

 

FDA Drug Warning: Codeine and Tramadol

 

Nationwide Recall of EpiPen and EpiPen Jr

 

Important Update: Biological and Biosimilar Products